OMER Stock Forecast: Omeros Corp. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Omeros Corp. hold a median 12-month price target of $28 — +108.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 81 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Omeros Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (91): The shares have been drifting up relative to others.
Volatility (22): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
OMER stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OMER, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +108.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Nov 2026 | HC Wainwright & Co. | Reiterates | Buy | $33 |
| 14 Oct 2026 | Cantor Fitzgerald | Reiterates | Overweight | $22 |
| 22 Sept 2026 | Cantor Fitzgerald | Upgrade | Overweight | $22 |
| 26 June 2026 | HC Wainwright & Co. | Maintains | Buy | $40 → $33 |
| 10 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 1 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Oct 2025 | Needham | Reiterates | Hold | — |
| 15 Oct 2025 | WBB Securities | Reiterates | Strong Buy | — |
| 3 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OMER.
This page is one stock. Monday covers all of them.
OMER appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
OMER vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Omeros Corp. returned +60.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
OMER analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 16.6×
- Price / sales
- 13.8×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 52% of US stocks
Cheaper than 10% of US stocks
- Revenue growth (YoY)
- 188.4%
- Earnings growth (YoY)
- —
- Gross margin
- 97.2%
- Operating margin
- −56.4%
- Net margin
- —
Higher than 95% of US stocks
Higher than 99% of US stocks
Higher than 17% of US stocks
- Return on equity
- —
- Return on assets
- −12.1%
- Dividend yield
- —
Higher than 25% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Omeros Corp. has a market value of $1.0B and an enterprise value of $1.1B.
Revenue in the twelve months to 30 June 2026: $38.4M.
Net income over the same four quarters: $124.8M, a 324.9% net margin.
Diluted earnings per share, trailing twelve months: $1.28.
Free cash flow in the twelve months to 30 June 2026: −$68.7M.
Omeros Corp. spent $9.9M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 16.6×; forward P/E: 12.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Omeros Corp. employs 175 people — $220K of revenue per employee.
Data provided by Twelve Data
OMER and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at OMER’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Omeros Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about OMER
What is the OMER stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Omeros Corp. have a median 12-month price target of $28, with estimates ranging from $22 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OMER stock a buy right now?
Of the 3 analysts covering Omeros Corp., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omeros Corp. 81 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OMER?
As at 21 Nov 2026, Omeros Corp. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).
Will OMER stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +108.2% from the last close, and Ticker Nerd's factor model ranks Omeros Corp. 81 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OMER stock forecast for 2030?
No analyst covering Omeros Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMER are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $33 over the next 12 months.
How has OMER stock performed over the past year?
Omeros Corp. returned +60.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Omeros Corp. do?
Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company concentrates on immunologic and complement-mediated diseases, along with selected orphan and rare indications affecting inflammation, coagulopathies, and central nervous system disorders.
About Omeros Corp.
Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company concentrates on immunologic and complement-mediated diseases, along with selected orphan and rare indications affecting inflammation, coagulopathies, and central nervous system disorders. Its portfolio includes commercial and development-stage programs designed to address unmet medical needs across hematology, nephrology, immunology, oncology, and addiction-related conditions. Omeros also works on targeted therapeutics that modulate the complement pathway, a key part of the immune system involved in several serious diseases. Headquartered in Seattle, Washington, Omeros Corp. plays a specialized role in the biotechnology market by advancing differentiated therapies from research through commercialization.
CEO Dr. Gregory A. Demopulos M.D. · 175 employees · United States · https://www.omeros.com